SEC Form 4 · accession 0001179110-18-009302
ACCELERON PHARMA INC · XLRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin F McLaughlin
Officer — SVP, CFO and Treasurer
Period of report
Jun 29, 2018
Accepted (ET)
Jul 3, 2018 · 2:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001280600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 29, 2018 | M | 25,000 | $24.11 | A | 68,939 | D | |
| Common Stock | Jun 29, 2018 | S | 12,500 | $47.00 | D | 56,439 | D | |
| Common Stock | Jun 29, 2018 | S | 12,500 | $49.00 | D | 43,939 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2 | $24.11 | Jun 29, 2018 | M | 25,000 | D | — | Dec 5, 2023 | Common Stock | 25,000 | 4,000 | D |
Explanation of responses
- F1The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.